SynthesisBMC medical genomics2026
Association between PNPLA3 rs738409 and susceptibility to etiology-specific liver cirrhosis: a systematic review and meta-analysis.
Synthesis in BMC medical genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular Mechanisms Associated with Metabolic Dysfunction: Contributions of Nutritional Genomics.Metabolites · 2026Review
- Hepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease.Circulation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimPNPLA3 rs738409 reduces the triglyceride hydrolase activity. This systematic review and meta-analysis aimed to assess the association between PNPLA3 rs738409 polymorphism and the risk of liver cirrhosis across various etiologies.
methodsPotential articles were selected from PubMed, Embase, Cochrane Library, and Web of Science databases, guided by well-defined inclusion and exclusion criteria. The quality of each article was rigorously evaluated using the Newcastle-Ottawa Scale (NOS). Association between PNPLA3 rs738409 and liver cirrhosis was expressed in terms of odds ratios (ORs) accompanied by 95% confidence intervals (CIs).
resultsThis meta-analysis encompassed 21 studies (22 tests, comprising 79102 controls and 4006 cases). The aggregate findings revealed a notable positive correlation between the rs738409 and the risk of liver cirrhosis across all genetic models: G vs. C (OR = 1.75, 95% CI = 1.64-1.86), GC vs. CC (OR = 1.77, 95% CI = 1.61-1.94), GG vs. CC (OR = 2.69, 95% CI = 2.34-3.08), GG vs. CG + CC (OR = 2.02, 95% CI = 1.79-2.28), and GG + CG vs. CC (OR = 1.99, 95% CI = 1.82-2.17). There was a pronounced heterogeneity observed across all genetic models, and might be induced by race and control groups. Subgroup analyses showed significant association respectively in Caucasian and Asian, as well as healthy controls, ALD and other liver diseases control types.
conclusionPNPLA3 rs738409 polymorphism has been robustly linked to an increased risk of etiology-specific liver cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.